In the need of novel strategies, in vivo studies provided convincing evidence that a dual blockade against PD-1 and the novel immune checkpoint receptor lymphocyte-associated gene-3 (LAG-3) [3] can result in tumor reduction and increase of survival [4, 5] by restoring CD8+ T cell function [6]. The gene discussed is PDCD1; the disease is neoplasm.